Karyopharm Therapeutics Inc. (KPTI)
KPTI moved a median of -0.45% 30 minutes after news, and -1.66% by the close. How KPTI actually reacts to news — the realized, point-in-time move the market made, measured across 392 labeled events over the last three years with zero look-ahead.
KPTI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 388 |
| 30-min | -0.45% | 45% | 391 |
| 60-min | -1.26% | 34% | 391 |
| to close | -1.66% | 37% | 388 |
| Middle 50% of KPTI reactions | -2.30% to +2.00% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 392 |
Half of all Karyopharm Therapeutics Inc. news events land between -2.30% and +2.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KPTI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 13 | +2.92% | 62% | -0.71% |
| Rating reiterations | 53 | -0.23% | 49% | -1.56% |
| Price-target cuts | 13 | +1.02% | 54% | -2.80% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how KPTI ranks against every other measured name →
That’s how KPTI usually reacts — get an email when it moves on news →Email me when KPTI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KPTI's baseline. Nothing else.
Recent KPTI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Karyopharm Therapeutics For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -5.10% | — | |
| Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.85% | -6.39% | |
| Form 8-K Karyopharm Therapeutics For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | +0.54% | |
| Form 8-K Karyopharm Therapeutics For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +6.00% | +7.33% | |
| Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.58% | -5.79% | |
| Form 8-K Karyopharm Therapeutics For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | +8.42% | |
| Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis | Press release | PR Newswire | -0.32% | +8.42% | |
| Form 10-Q Karyopharm Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.80% | -3.87% | |
| Form 8-K Karyopharm Therapeutics For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | -3.87% | |
| Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission | Press release | PR Newswire | +0.80% | -3.87% | |
| Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 | Press release | PR Newswire | +1.22% | — | |
| Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +1.00% | -2.00% | |
| Form 8-K Karyopharm Therapeutics For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +7.31% | -12.33% | |
| Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer | Press release | PR Newswire | +7.31% | -12.33% | |
| Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway | Press release | PR Newswire | +7.31% | -12.33% | |
| Form 8-K Karyopharm Therapeutics For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -7.41% | -20.95% | |
| Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.00% | -1.03% | |
| Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 | Press release | PR Newswire | +0.64% | +0.78% | |
| Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology | Press release | PR Newswire | +0.14% | -5.91% | |
| Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 | Press release | PR Newswire | -0.26% | -1.18% | |
| Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.14% | -5.91% | |
| Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation | Press release | PR Newswire | -1.94% | +5.82% | |
| Form 8-K Karyopharm Therapeutics For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -0.22% | |
| Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference | Press release | PR Newswire | -0.95% | +1.45% | |
| Form S-8 Karyopharm Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -0.95% | +1.45% | |
| Form EFFECT Karyopharm Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -0.24% | -12.84% | |
| Form 10-Q Karyopharm Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.58% | -6.32% | |
| Form 8-K Karyopharm Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +5.58% | -6.32% | |
| Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | Press release | PR Newswire | +5.58% | -6.32% | |
| Karyopharm to Participate at Upcoming Investor Conferences | Press release | PR Newswire | +1.81% | +0.85% | |
| Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | PR Newswire | +0.00% | -1.23% | |
| Form S-3 Karyopharm Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +2.26% | +1.07% | |
| Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting | Press release | PR Newswire | -0.06% | +1.66% | |
| Form ARS Karyopharm Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.63% | +4.02% | |
| Form DEF 14A Karyopharm Therapeutics For: Apr 13 | SEC filing · Form DEF | SEC EDGAR | +1.63% | +4.02% | |
| Form 8-K Karyopharm Therapeutics For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +1.81% | -0.54% | |
| Form 8-K Karyopharm Therapeutics For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +2.48% | -10.08% | |
| Karyopharm Announces $30 Million Private Placement with RA Capital | Press release | PR Newswire | +2.48% | -10.08% | |
| Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction | Press release | PR Newswire | +2.48% | -10.08% | |
| Form 8-K Karyopharm Therapeutics For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -4.60% | |
| Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.10% | -4.60% | |
| Form 8-K Karyopharm Therapeutics For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | -0.31% | |
| Form 10-K Karyopharm Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.45% | -4.45% | |
| Form 8-K Karyopharm Therapeutics For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +14.73% | +33.04% | |
| Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress | Press release | PR Newswire | +14.73% | +33.04% | |
| Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | Press release | PR Newswire | -0.70% | -5.29% | |
| Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +3.10% | +3.97% | |
| Form 8-K Karyopharm Therapeutics For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | -5.15% | |
| Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 | Press release | PR Newswire | -3.85% | -5.15% | |
| Form DEF 14A Karyopharm Therapeutics For: Feb 18 | SEC filing · Form DEF | SEC EDGAR | -3.85% | -5.15% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KPTI section they belong to.
Where else KPTI is measured.
KPTI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| BioXcel Therapeutics, Inc. (BTAI) | 392 | -0.75% | 41% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 391 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Karyopharm Therapeutics Inc.'s median reaction calculated?
Every labeled KPTI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 392 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of KPTI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KPTI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.